Stock Research: Harmony Biosciences Holdings

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Harmony Biosciences Holdings

NasdaqGM:HRMY US4131971040
86
  • Value
    96
  • Growth
    87
  • Safety
    Safety
    50
  • Combined
    96
  • Sentiment
    43
  • 360° View
    360° View
    86
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Harmony Biosciences Holdings, Inc. is a pharmaceutical company focused on therapies for rare and other neurological diseases. Its main business is developing and commercializing treatments like WAKIX for narcolepsy, and investigational compounds like HBS-102, ZYN002, EPX-100, and EPX-200 for conditions such as Fragile X syndrome, 22q11.2 deletion syndrome, and epilepsy. The company operates in the pharmaceutical and neuroscience sectors, with product development primarily in neurological disease therapies. In the last fiscal year, the company had a market cap of $2010 million, profits of $558 million, and revenue of $715 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 86 (better than 86% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Harmony Biosciences Holdings are very positive. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Harmony Biosciences Holdings. The consolidated Value Rank has an attractive rank of 50, which means that the share price of Harmony Biosciences Holdings is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 50% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 87, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 96. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 43. Professional investors are more confident in 57% other stocks. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
50 32 34 17
Growth
87 91 51 100
Safety
Safety
96 86 43 43
Sentiment
43 96 83 100
360° View
360° View
86 98 34 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
28 40 17 81
Opinions Change
20 70 69 50
Pro Holdings
n/a 100 82 92
Market Pulse
75 83 95 90
Sentiment
43 96 83 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
50 32 34 17
Growth
87 91 51 100
Safety Safety
96 86 43 43
Combined
96 96 59 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
75 67 85 64
Price vs. Earnings (P/E)
47 41 31 28
Price vs. Book (P/B)
47 31 18 4
Dividend Yield
1 1 1 1
Value
50 32 34 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
76 74 82 81
Profit Growth
65 39 20 100
Capital Growth
90 97 91 94
Stock Returns
43 71 17 67
Growth
87 91 51 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
64 56 49 23
Refinancing
59 49 53 21
Liquidity
84 82 100 100
Safety Safety
96 86 43 43

Similar Stocks

Discover high‑ranked alternatives to Harmony Biosciences Holdings and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.